Chamaeleo Pharma hires Han Van t Klooster as Vice President of Commercial Operations

He joins the Belgian company from Pharmion Europe

Belgian oncology company Chamaeleo Pharma says Han Van ‘t Klooster has joined the company as Vice President of Commercial Operations.

Van ‘t Klooster will be a member of Chamaeleo’s Management team and will be responsible for the market access and commercial launch of the company’s lead product Fosfestrol for the treatment of advanced prostate cancer.

Van ‘t Klooster has more than 20 years of business experience in the pharmaceutical industry. Prior to joining Chamaeleo, he was General Manager of Pharmion Europe (acquired by Celgene).

Prior to this, he was International Marketing Director Oncology at Chiron Corporation (acquired by Novartis). He started his career at AstraZeneca as a Product Manager.

You may also like

Manufacturing

Innovation in generics: increased efficiency through peptide API synthesis expertise

Leading Swiss pharmaceutical company Bachem explains the benefits of converging LPPS in the manufacturing of gonadotropin-releasing hormone (GnRH) analogues
Regulatory

Broughton receives flexible scope ISO 17025 accreditation

New certification allows accreditation without prior approval
Research & Development

N4 Pharma and SRI to target and treat previously unreachable human cells

The companies will collaborate to perform research to conjugate SRI’s MGS system to Nuvec to increase intracellular delivery to specific target cells.
Finance

Berry Global invests to increase production capacity for healthcare products

Berry Global Group has invested in additional assets and manufacturing capabilities to increase its healthcare production capacity by up to 30% across three of its European sites
Manufacturing

For easy transition from glass to plastic accessories - BOLA components with GL threads

The GL thread is the most common thread on lab equipment made of glass. Available from Labtex in the UK, BOLA offers a modular construction system with many different components with GL threads
Distribution

ChargePoint invest in a single-use manufacturing facility to expand product line

The single-use manufacturing facility will become fully operational in June 2024, and will support the company's trio of liquid and powder transfer devices
Research & Development

Owlstone Medical bags $6.5m to optimise infectious disease diagnostic tool

The Bill & Melinda Gates Foundation has funded the bolstering of the Breath Biopsy platform, as well as research into breath biomarkers in tuberculosis (TB) and HIV
Subscribe now